Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report
Executive Summary
FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement